Natera presented real‑world data at ASH showing that circulating tumor DNA (ctDNA) minimal residual disease testing at end‑of‑treatment was prognostic across lymphoma subtypes and outperformed PET scans for risk stratification. Investigators reported ctDNA positivity correlated with worse outcomes and could refine post‑therapy surveillance. Presenters argued ctDNA MRD could inform earlier intervention and accelerate trials by serving as a more sensitive biomarker than imaging in some settings. The data add to growing evidence for liquid biopsy applications in hematologic malignancies.